hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06335901, orgStudyIdInfo id: xx20190901, briefTitle: Clinical Characteristics and Outcomes of Coronary Heart Disease, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-02-01, primaryCompletionDateStruct date: 2022-01-31, completionDateStruct date: 2022-04-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Xinjiang Medical University, class: OTHER, descriptionModule briefSummary: This study evaluated and compared the prognostic value of different Baseline data and clinical variables to develop a risk ractor ediction model in patients with CHD., conditionsModule conditions: Coronary Heart Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20000, type: ACTUAL, armsInterventionsModule interventions name: Drug:Standard therapy, outcomesModule primaryOutcomes measure: Death （All-cause mortality、Cardiac mortality ）, secondaryOutcomes measure: Major adverse cardiovascular events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Xinjiang Medical University, city: Ürümqi, state: Xinjiang, zip: 630000, country: China, geoPoint lat: 43.80096, lon: 87.60046, hasResults: False
protocolSection identificationModule nctId: NCT06335888, orgStudyIdInfo id: CRAFT, briefTitle: A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis, acronym: CRAFT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2029-05, completionDateStruct date: 2029-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Insel Gruppe AG, University Hospital Bern, class: OTHER, collaborators name: Paul Scherrer Institut, Center for Proton Therapy, descriptionModule briefSummary: The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-\[18F\]FDG-PET/CT, and to assess the safety and tolerability of AzaFol in subjects with suspicion of GCA.Participants will undergo AzaFol-PET/CT imaging at a single timepoint., conditionsModule conditions: Giant Cell Arteritis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Cross-over, randomized, open label, single-centre, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: AzaFol, interventions name: FDG, outcomesModule primaryOutcomes measure: Specificity of the GCA-diagnosis at the patient level, secondaryOutcomes measure: Lesion detection rate (visual analysis), secondaryOutcomes measure: Lesion detection rate (semiquantitative analysis), secondaryOutcomes measure: Sensitivity of the GCA-diagnosis at the patient level, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Rheumatology and Immunology, University Hospital Bern, Inselspital, city: Bern, zip: 3010, country: Switzerland, contacts name: Britta Maurer, role: CONTACT, geoPoint lat: 46.94809, lon: 7.44744, hasResults: False
protocolSection identificationModule nctId: NCT06335875, orgStudyIdInfo id: HUM00227568, briefTitle: Brain Small Chain Fatty Acid Metabolism in Bipolar Disorder: Ketones, acronym: BIPO, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, descriptionModule briefSummary: Small exploratory open-label pilot study to assess supplementation of a ketone ester (Juvenescence) combined with a 'ketogenic-mimicking diet' as a potential therapy for persons with bipolar disorder., conditionsModule conditions: Bipolar Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Ketone Ester Beverage, interventions name: Low Glycemic Index Diet, outcomesModule primaryOutcomes measure: Change in blood beta-hydroxybutyrate level, secondaryOutcomes measure: Change in blood glucose lability, secondaryOutcomes measure: Change in neural network stability, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Domino's Farms, city: Ann Arbor, state: Michigan, zip: 48105, country: United States, geoPoint lat: 42.27756, lon: -83.74088, locations facility: University Hospital, city: Ann Arbor, state: Michigan, zip: 48109, country: United States, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False
protocolSection identificationModule nctId: NCT06335849, orgStudyIdInfo id: LYB004-CT-AUS-101, briefTitle: A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Guangzhou Patronus Biotech Co., Ltd., class: INDUSTRY, collaborators name: Yantai Patronus Biotech Co., Ltd., descriptionModule briefSummary: This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years., conditionsModule conditions: Herpes Zoster, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: LYB004 25µg, interventions name: LYB004 50µg, interventions name: SHINGRIX, outcomesModule primaryOutcomes measure: Evaluate the reactogenicity of LYB004 vaccine, primaryOutcomes measure: Evaluate the safety and reactogenicity of LYB004 vaccine, primaryOutcomes measure: Evaluate the safety of LYB004 vaccine, primaryOutcomes measure: Evaluate the safety and tolerability in laboratory tests of LYB004 vaccine, primaryOutcomes measure: Evaluate the SAEs and AESIs of LYB004 vaccine, secondaryOutcomes measure: Observe the humoral immunity of LYB004 vaccine, secondaryOutcomes measure: Observe the cellular immunity of LYB004 vaccine, secondaryOutcomes measure: Observe the persistence of humoral immunity of LYB004 vaccine, secondaryOutcomes measure: Observe the persistence of cellular immunity of LYB004 vaccine, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nucleus Network Pty Ltd, city: Melbourne, state: Victoria, zip: 3004, country: Australia, contacts name: Katherine Gunn, role: CONTACT, phone: (07) 3707 2781, email: k.gunn@nucleusnetwork.com.au, contacts name: Kristof Boot, role: CONTACT, phone: (07) 3707 2780, email: k.boot@nucleusnetwork.com.au, contacts name: Christina Chang, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: -37.814, lon: 144.96332, hasResults: False
protocolSection identificationModule nctId: NCT06335823, orgStudyIdInfo id: STUDY20231621, briefTitle: Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Reduction During Intrauterine Device (IUD) Insertion in Outpatient Gynecology, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-08-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Jean Marino, class: OTHER, descriptionModule briefSummary: Pain with intrauterine device (IUD) insertion is very common and there are few options for patients to help reduce this pain. Transcutaneous electric nerve stimulators (TENS) are a non-invasive procedure that may help reduce the pain with IUD insertions. The investigators hope that the information gleaned from this study will result in pain control options for future patients who desire an IUD placement., conditionsModule conditions: IUD Insertion Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Transcutaneous electrical nerve stimulation (TENS), interventions name: Placebo Transcutaneous electrical nerve stimulation (TENS), outcomesModule primaryOutcomes measure: Pain during IUD insertion as measured by the VAS score, secondaryOutcomes measure: Pain during IUD insertion as measured by the VAS score, secondaryOutcomes measure: Pain during IUD insertion as measured by the VAS score, secondaryOutcomes measure: Pain during IUD insertion as measured by the VAS score, secondaryOutcomes measure: Pain during IUD insertion as measured by the VAS score, otherOutcomes measure: Pain during IUD insertion as measured by the VAS score, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: University Hospitals, city: Cleveland, state: Ohio, zip: 44106, country: United States, contacts name: Jean M Marino, APRN-CNP, role: CONTACT, phone: 440-720-3250, email: Jean.Marino@UHhospitals.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06335797, orgStudyIdInfo id: IRB00110733, briefTitle: Optimization of Postoperative Bowel Habits, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Wake Forest University Health Sciences, class: OTHER, descriptionModule briefSummary: Project is a trial, in which women undergoing vaginal surgery for pelvic organ prolapse will be randomized 1:1 to a postoperative bowel regimen of either oral senna or rectal bisacodyl suppository., conditionsModule conditions: Constipation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 88, type: ESTIMATED, armsInterventionsModule interventions name: Senna Tab, interventions name: Dulcolax Suppositories, outcomesModule primaryOutcomes measure: Time in hours to first bowel movement comparison between the two arms, secondaryOutcomes measure: Change in Overall Satisfaction (TSQM) Scores, secondaryOutcomes measure: Visual Analog Scale (VAS) Pain Scores, secondaryOutcomes measure: Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) Scores, secondaryOutcomes measure: Bristol Stool Form Scale (BSFS) Scores, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wake Forest University Health Sciences, city: Winston-Salem, state: North Carolina, zip: 27157, country: United States, contacts name: Christina M Mezes, MD, role: CONTACT, phone: 336-713-4098, email: cmezes@wakehealth.edu, contacts name: Sachin N Vyas, MS, PhD, role: CONTACT, phone: 336.713.4098, email: svyas@wakehealth.edu, geoPoint lat: 36.09986, lon: -80.24422, hasResults: False
protocolSection identificationModule nctId: NCT06335771, orgStudyIdInfo id: 2098077, secondaryIdInfos id: R01DK131188, type: NIH, link: https://reporter.nih.gov/quickSearch/R01DK131188, briefTitle: Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity, acronym: ATM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2028-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Bettina Mittendorfer, class: OTHER, collaborators name: National Institutes of Health (NIH), collaborators name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), descriptionModule briefSummary: The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.Both groups will have:* screening visit* imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and magnetic resonance spectroscopy \[MRS\] scans)* Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss., conditionsModule conditions: Obesity, conditions: Nonalcoholic Fatty Liver, conditions: Diabetes Type 2, conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Dietary consultation weight loss intervention, outcomesModule primaryOutcomes measure: Insulin sensitivity assessed as insulin-mediated glucose disposal during a hyperinsulinemic-euglycemic clamp procedure., primaryOutcomes measure: 24-hour plasma glucose concentration, primaryOutcomes measure: Macrophage isolation in adipose tissue biopsy, primaryOutcomes measure: Macrophage isolation in skeletal muscle tissue, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Missouri School of Medicine, city: Columbia, state: Missouri, zip: 65212, country: United States, contacts name: Bettina Mittendorfer, role: CONTACT, phone: 573-822-9377, email: b.mittendorfer@missouri.edu, geoPoint lat: 38.95171, lon: -92.33407, hasResults: False
protocolSection identificationModule nctId: NCT06335758, orgStudyIdInfo id: EXC-039-2023-CLR, briefTitle: Non-randomized Observational Study to Evaluate ReX® in the Management of Solid Oral Medication., acronym: RegStud, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Dosentrx Ltd., class: INDUSTRY, collaborators name: US Oncology Research, descriptionModule briefSummary: The goal of this observational study is to evaluate the safety, efficacy and patient satisfaction with the ReX Remote Digital Nurse by patients receiving solid oral medication.The study will evaluate and monitor use of ReX in respect of:* treatment duration* adverse events* patient adherence and compliance* engagement with ReX via patient-reported outcomesPatients participating in the study will receive their normal medication as standard of care via ReX. Progress will be monitored via patients' responses to questions presented on the ReX touch screen., conditionsModule conditions: Any Solid Oral Medication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Use of ReX to dispense and monitor solid oral medication therapy., outcomesModule primaryOutcomes measure: Treatment duration, primaryOutcomes measure: Patient satisfaction, primaryOutcomes measure: Adverse events, primaryOutcomes measure: Patient adherence, primaryOutcomes measure: Patient compliance, primaryOutcomes measure: Patient engagement, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: OHC, status: RECRUITING, city: Cincinnati, state: Ohio, zip: 45242, country: United States, contacts name: Zachary Beck, role: CONTACT, geoPoint lat: 39.12713, lon: -84.51435, hasResults: False
protocolSection identificationModule nctId: NCT06335745, orgStudyIdInfo id: 24-066, briefTitle: PediCARE Health Equity Intervention in High-Risk Neuroblastoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2028-04-01, completionDateStruct date: 2030-04-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Dana-Farber Cancer Institute, class: OTHER, descriptionModule briefSummary: This is a randomized Phase II trial evaluating the addition of the Pediatric Cancer Resource Equity (PediCARE) health equity intervention to usual supportive care for poverty-exposed children with newly diagnosed high-risk neuroblastoma.The names of the intervention groups in this research study are:* Usual supportive care* PediCARE + usual supportive care, conditionsModule conditions: Neuroblastoma, conditions: High-risk Neuroblastoma, conditions: Pediatric Cancer, conditions: Disparities, conditions: Financial Stress, conditions: Poverty, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: PediCARE Intervention, outcomesModule primaryOutcomes measure: Change in Kessler-6 Psychological Distress Scale Score, secondaryOutcomes measure: Proportion of Enrolled Participants (Feasibility), secondaryOutcomes measure: Change in Mean Household Material Hardship (HMH) Score, eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Boston Children's Hospital, city: Boston, state: Massachusetts, zip: 02215, country: United States, geoPoint lat: 42.35843, lon: -71.05977, locations facility: Dana Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06335732, orgStudyIdInfo id: P.T.REC/012/004394, briefTitle: Prevalenc Of Lumbosacral Radiculopathy Among Physiotherapists Of Pediatric Rehabilitation OF PEDIATRIC REHABILITATION, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-05, primaryCompletionDateStruct date: 2023-06-08, completionDateStruct date: 2023-08-22, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Kerolous Ishak Shehata, class: OTHER, descriptionModule briefSummary: Determine the prevalence of lumbosacral radiculopathy among pediatric physiotherapists in the ministry of health in Cairo, Egypt., conditionsModule conditions: Prevalence, Lumbosacral Radiculopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200, type: ACTUAL, armsInterventionsModule interventions name: Cross section study; single group related measurement design., outcomesModule primaryOutcomes measure: The Roland-Morris disability scale (RMS), primaryOutcomes measure: Straight Leg Raising (SLR), eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Kerolous Ishak Shehata, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06335719, orgStudyIdInfo id: IRB #22-926, briefTitle: Intraoperative Electrical Stimulation to Improve Nerve Grafting Outcome, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: The Cleveland Clinic, class: OTHER, descriptionModule briefSummary: A research study to find out if brief intraoperative electrical stimulation therapy improves nerve regeneration and smile outcomes following two-stage cross face nerve graft facial reanimation surgery., conditionsModule conditions: Facial Paralysis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients will undergo all the standard steps of the facial reanimation procedures. The difference in care is 2/3 participants may receive the brief electrical stimulation therapy.Other 1/3 of study participants will undergo the surgery as they normally would if they had not chosen to participate., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: This is a randomized, controlled, double-blinded (patient and evaluator) prospective study. Plan is to enroll up to 30 patients, with a minimum of 20 completing full follow-up. Randomization 2:1 treatment to control due to previous peripheral nerve research demonstrating intraoperative stimulation accelerates axonal regeneration, whoMasked: PARTICIPANT, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: BES, interventions name: Standard of Care surgery, outcomesModule primaryOutcomes measure: To evaluate efficacy of an intraoperative dose of brief electrical stimulation (BES) to improve axonal regeneration across a cross-face nerve graft (CFNG) using nerve histology., secondaryOutcomes measure: To evaluate clinical outcomes of treatment and control groups using patient reported, and IRB approved CCF Facial Nerve Survey., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland Clinic Foundation, status: RECRUITING, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Hana Rosen, MD, role: CONTACT, phone: 216-444-7018, email: rosenh@ccf.org, contacts name: John O'Neill, BS, role: CONTACT, phone: 4405062611, email: oneillj2@ccf.org, contacts name: Patrick Byrne, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Michael Fritz, MD, role: SUB_INVESTIGATOR, contacts name: Brandon Hopkins, MD, role: SUB_INVESTIGATOR, contacts name: Peter Ciolek, MD, role: SUB_INVESTIGATOR, contacts name: Dane Genther, MD, role: SUB_INVESTIGATOR, contacts name: Stephen Hadford, MD, role: SUB_INVESTIGATOR, contacts name: Peng Ding, MD, role: SUB_INVESTIGATOR, contacts name: Derek Vos, BS, role: SUB_INVESTIGATOR, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False